GW Pharmaceuticals announced plans to expand their research agenda by investigating the therapeutic potential of new cannabis-ethanol sprays into the realm of metabolic diseases such as Obesity and Type II Diabetes.

For this project, GW is teaming up with Mike Cawthorne, the group director of the research team that “discovered the multi-billion dollar insulin sensitizer drug, Rosigilatzone.”

The new cannabis spray will be extracted from plants which contain high amounts of CBD and THCV. CBD has shown potential to treat fatty liver diseases and hpercholesterolaemia and also blocks the psychoactive effects of Delta9-THC. THCV, a natural antagonist or Cannabinoid receptor blocker, has notable effects on increasing energy expenditure. THCV, unlike Delta9-THC, is usually present only in small concentrations on the plant. However, GW may have developed a so called THCV-rich cannabis plant.

Developing a treatment for a complex illness, such as metabolic syndrome, can be explored using two cannabinoids in combination and can potentially “be addressed with a single medicine.”

Please donate! Every dollar helps this site bring you the latest scientific findings!
Thanks,
Jahan